文献速递血液透析通路

MAUDE数据库对510(k)授权有何启示?两代血管内动静脉瘘装置的评估

What is the MAUDE Database Telling us about 510(k) Authorization? Evaluation of Two Generations of Endovascular Arteriovenous Fistula Devices.
PubMed 文献 · Ann Vasc Surg · 2024-05-28

研究查询FDA制造商与用户设施器械经验数据库,比较WavelinQ EndoAVF系统与其510(k)参照器械WavelinQ 4F EndoAVF系统的不良事件报告。WavelinQ 4F组125份报告,WavelinQ组78份;WavelinQ组患者问题「高血压」显著增加(0% vs 5.1%,P=0.02),器械问题「对齐失败」显著减少(24.8% vs 10.3%,P≤0.01)。

要点

  • WavelinQ组患者问题高血压报告比例较WavelinQ 4F组升高(0% vs 5.1%,P=0.02)。
  • WavelinQ组器械问题对齐失败报告比例较WavelinQ 4F组降低(24.8% vs 10.3%,P≤0.01)。
  • 作者认为这凸显FDA MAUDE报告在510(k)上市后维持器械安全中的重要性。

核心结论

  • WavelinQ EndoAVF系统与WavelinQ 4F EndoAVF系统之间的器械与患者结局存在变化。
  • 器械问题「对齐失败」减少,但患者「高血压」报告率总体增加。
  • 作者认为这凸显FDA MAUDE报告在确保经510(k)流程获批上市的器械维持安全方面的重要性。

研究设计与样本

  • 查询FDA制造商与用户设施器械经验数据库(MAUDE)中WavelinQ EndoAVF系统与WavelinQ 4F EndoAVF系统的所有不良事件报告。
  • 收集患者问题与器械问题数据,采用Fisher精确检验。
  • WavelinQ 4F EndoAVF系统共125份报告,WavelinQ EndoAVF系统共78份报告。

主要发现

  • 患者问题「高血压」:WavelinQ组5.1% vs WavelinQ 4F组0%,P=0.02,WavelinQ组显著增加。
  • 器械问题「对齐失败」:WavelinQ组10.3% vs WavelinQ 4F组24.8%,P≤0.01,WavelinQ组显著减少。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In 2019, Bard Peripheral Vascular Inc (BV; now Becton, Dickinson and Company; Sparks, Maryland) received Food and Drug Administration (FDA) approval to begin marketing the WavelinQ EndoAVF System through a process known as 510(k) authorization. Such authorization relies on BV proving that the new WavelinQ EndoAVF System was of "substantial equivalence" to the WavelinQ 4F EndoAVF System. We set forth to analyze patient problems and device issues reported for the new device and determine if they were significantly different from the predicate device its 510(k) approval was based on. METHODS: FDA database Manufacturer and User Facility Device Experience was queried for all adverse report events for the WavelinQ EndoAVF System and WavelinQ 4F EndoAVF System. Data were collected on patient issues and device issues. Fisher's exact test was used. RESULTS: There were a total of 125 reports for the WavelinQ 4F EndoAVF System and 78 for the WavelinQ EndoAVF System. There was a significant increase in patient problem "hypertension" (0% vs. 5.1%; P = 0.02) for the WavelinQ EndoAVF System but a statistically significant decrease in device issue "failure to align" for the WavelinQ EndoAVF System (24.8% vs. 10.3%; P ≤ 0.01). CONCLUSIONS: There were changes in device and patient outcomes between the WavelinQ EndoAVF System and WavelinQ 4F EndoAVF System. While we noted a decrease in device problem "failure to align", there was an overall increase in patients' "hypertension" rates. This highlights the importance of the FDA Manufacturer and User Facility Device Experience reporting in ensuring that device safety is maintained when devices are approved for marketing through the 510(k) process.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Hogan D, Otoya D, Lavingia K, et al. What is the MAUDE Database Telling us about 510(k) Authorization? Evaluation of Two Generations of Endovascular Arteriovenous Fistula Devices. Ann Vasc Surg. 2024. PMID: 38815918. doi:10.1016/j.avsg.2024.03.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。